Article Information
History
- August 24, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- 1Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, U.S.A
- 2Molecular Biology Interdepartmental Ph.D. Program, University of California, Los Angeles, CA 90095, U.S.A
- 3Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, U.S.A
- 4Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095, U.S.A
- 5Molecular Biology Institute, University of California, Los Angeles, CA 90095, U.S.A
- ↵*Corresponding authors. Email: F.G. fguo{at}mbi.ucla.edu; V.A. varumugaswami{at}mednet.ucla.edu
Posted August 24, 2021.
Structure-based design of antisense oligonucleotides that inhibit SARS-CoV-2 replication
